Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | PREP | P48147 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17154296 | 1.00 | HSD17B10 (0.39) | HSD17B10CHRM2CHRM1CHRM3NR1H2 | |
| SCHEMBL874850 | 1.00 | HSD17B10 (0.39) | HSD17B10CHRM2CHRM1CHRM3NR1H2 | |
| SCHEMBL875482 | 1.00 | HSD17B10 (0.39) | HSD17B10CHRM2CHRM1CHRM3NR1H2 | |
| SCHEMBL882934 | 0.87 | CHRM2 (0.38) | HSD17B10CHRM2CHRM1CHRM3NR1H2 | |
| SCHEMBL15423568 | 0.87 | CHRM2 (0.38) | HSD17B10CHRM2CHRM1CHRM3NR1H2 | |
| SCHEMBL18094053 | 0.87 | HSD17B10 (0.40) | HSD17B10CHRM2CHRM1CHRM3NR1H2 | |
| SCHEMBL30591306 | 0.87 | HSD17B10 (0.40) | HSD17B10CHRM2CHRM1CHRM3NR1H2 | |
| SCHEMBL18611180 | 0.87 | HSD17B10 (0.40) | HSD17B10CHRM2CHRM1CHRM3NR1H2 | |
| SCHEMBL15116885 | 0.87 | HSD17B10 (0.40) | HSD17B10CHRM2CHRM1CHRM3NR1H2 | |
| SCHEMBL1314629 | 0.85 | HSD17B10 (0.40) | HSD17B10CHRM2CHRM1CHRM3NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2012040242-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, EIF2AK2, PREP | HSD17B10 2966/4885CHRM2 4758/4885CHRM1 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.